HSTM vs. OMCL, MDRX, CRTX, IAC, GRND, DOCN, RUM, VNET, WB, and DV
Should you be buying HealthStream stock or one of its competitors? The main competitors of HealthStream include Omnicell (OMCL), Veradigm (MDRX), Cortexyme (CRTX), IAC (IAC), Grindr (GRND), DigitalOcean (DOCN), Rumble (RUM), VNET Group (VNET), Weibo (WB), and DoubleVerify (DV).
HealthStream vs.
HealthStream (NASDAQ:HSTM) and Omnicell (NASDAQ:OMCL) are both small-cap computer and technology companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, dividends, valuation, risk, institutional ownership and community ranking.
In the previous week, Omnicell had 5 more articles in the media than HealthStream. MarketBeat recorded 8 mentions for Omnicell and 3 mentions for HealthStream. HealthStream's average media sentiment score of 1.73 beat Omnicell's score of 0.63 indicating that HealthStream is being referred to more favorably in the media.
69.6% of HealthStream shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 20.6% of HealthStream shares are owned by company insiders. Comparatively, 2.6% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
HealthStream has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.85, meaning that its share price is 15% less volatile than the S&P 500.
HealthStream has a net margin of 6.84% compared to Omnicell's net margin of 1.13%. HealthStream's return on equity of 5.67% beat Omnicell's return on equity.
HealthStream has higher earnings, but lower revenue than Omnicell. HealthStream is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.
HealthStream currently has a consensus price target of $32.00, suggesting a potential downside of 0.09%. Omnicell has a consensus price target of $51.00, suggesting a potential upside of 45.13%. Given Omnicell's higher possible upside, analysts plainly believe Omnicell is more favorable than HealthStream.
Omnicell received 38 more outperform votes than HealthStream when rated by MarketBeat users. Likewise, 66.80% of users gave Omnicell an outperform vote while only 66.52% of users gave HealthStream an outperform vote.
Summary
HealthStream beats Omnicell on 10 of the 18 factors compared between the two stocks.
Get HealthStream News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSTM and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
HealthStream Competitors List
Related Companies and Tools
This page (NASDAQ:HSTM) was last updated on 3/25/2025 by MarketBeat.com Staff